Abbreviations: AE, adverse event; AUC, area under the concentration-time curve; AUC inf , area under the concentration-time curve from 0 to infinity; AUC last , area under the concentration-time curve from time 0 to the last quantifiable concentration; BMI, body mass index; This study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of various doses of the anti-CD40 monoclonal antibody bleselumab (ASKP1240) in de novo kidney transplant recipients receiving concomitant standard immunosuppression over 90 days posttransplant. Transplant recipients were randomized (1:1:1:1:1) to bleselumab 50 mg, 100 mg, 200 mg, or 500 mg, or placebo, in addition to standard maintenance immunosuppression. The primary pharmacokinetic endpoints were AUC inf , C max , and AUC last . The primary pharmacodynamic endpoint was B cell CD40 receptor occupancy over time. Overall, 50 kidney transplant recipients were randomized; 45 received their randomized treatment (bleselumab [n = 37] or placebo [n = 8]). AUC inf and AUC last demonstrated a more than dose-proportional increase in the range of 50-500 mg, and C max increased linearly with increasing dose. Maximal receptor occupancy for B cell CD40 was reached at all dose levels and was prolonged as dose increased. No kidney transplant recipients experienced cytokine release syndrome or a thromboembolic event. Treatment-emergent anti-bleselumab antibodies were found in one kidney transplant recipient in the bleselumab 50 mg group; these were detected only at Day 7. Overall, bleselumab demonstrated nonlinear pharmacokinetics and dose-dependent prolonged B cell CD40 receptor occupancy and was well tolerated at all doses (ClinicalTrials.gov: NCT01279538). K E Y W O R D S antibody biology, clinical research/practice, kidney transplantation/nephrology, kidney transplantation: living donor
| INTRODUC TI ON
Over the past 30 years, the search for effective calcineurin inhibitor (CNI)-free regimens has been focused on biologics that target the receptors and ligands of the costimulatory pathway. Two important factors in the pathway have emerged as critical for T cell and B cell activation. These are the CD28-CD80/CD86 receptor-ligands and the CD40-CD154 (CD40L) receptor-ligands. 1, 2 Targeting these pathways in experimental models and in human kidney transplant recipients occurred simultaneously, and the first approved costimulation blocking agent for the prophylaxis of kidney transplant rejection, belatacept, targeted the CD28-CD80/CD86 pathway. [3] [4] [5] The first phase 2 study in kidney transplantation to target costimulation was with a humanized CD154 antibody, hu5c8. 6 The study utilized a CNI-free regimen that had induced prolonged graft survival and even tolerance in some nonhuman primates. These exciting in vivo findings are consistent with the important role of the CD40-CD154 pathway in T cell and B cell activation. CD40 is expressed on antigen-presenting cells, B cells, and macrophages, [7] [8] [9] whereas CD154 is upregulated on activated T cells. 10 CD40-CD154 participates in T cell activation by upregulating the ligands for CD28, and is critical in B cell activation and differentiation. 1, 2 Hu5c8 as well as other anti-CD154 antibodies was halted from clinical development because of the occurrence of thromboembolic complications due in part to the upregulation of CD154 on platelets. 11, 12 However, interest in pursuing blockade of the CD40-CD154 pathway persisted and antibodies targeting the CD40 receptor instead emerged as an effective alternative. 11, 13, 14 Bleselumab (ASKP1240) is a fully human immunoglobulin G4 anti-CD40 monoclonal antibody that inhibits both humoral (immunoglobulin production) and cellular immune responses by blocking the interaction of CD40:CD154 between T cells, B cells, and antigen-presenting cells. 2, 11 Results from in vitro and in vivo studies have suggested a potential therapeutic role for bleselumab as an immunosuppressive therapy in transplant recipients. 11 In a phase 1 study in healthy volunteers, bleselumab was well tolerated, with no evidence of cytokine release syndrome or thromboembolic events. 15 Bleselumab demonstrated nonlinear pharmacokinetics in the dose range of 0.1-10 mg/kg, with mean maximum serum concentrations (C max ) and area under the serum concentration-time curves (AUC) ranging from 0.7 to 252 μg/mL and 6.5 to 55 410 μg·h/mL, respectively. 15 Here we describe the results of a phase 1b, single-dose, placebocontrolled multicenter study that evaluated the pharmacokinetics, pharmacodynamics, safety, and tolerability of four dose levels of bleselumab administered with standard immunosuppressants to de novo kidney transplant recipients.
| MATERIAL S AND ME THODS

| Study design
This phase 1b, single-dose, double-blind, parallel-group, placebocontrolled multicenter study was conducted at 15 sites in the United States between November 17, 2010 and January 23, 2012 (NCT01279538). Patients were screened between 14 days pretransplant and 2 days posttransplant and were then randomized in a 1:1:1:1:1 ratio (1-4 days posttransplant) to receive a single 30-minute infusion of bleselumab 50 mg, 100 mg, 200 mg, or 500 mg, or placebo ( Figure 1 ). The day of infusion was defined as Day 1, after which patients were followed for 90 days. Institutional review board/independent ethics committee approval of the protocol (protocol number 7163-CL-0103), informed consent, and patient information were obtained before initiation of any study-specific procedures (see Table S1 for a list of institutional review boards).
| Transplant recipients
Adult (18-65 years of age) de novo kidney transplant recipients who received their kidney from either a living or deceased donor were randomized. Before randomization, subjects had to have a posttransplant serum creatinine value that was ≥30% less than the pretransplant value and required no dialysis. Exclusion criteria included subjects who were receiving antibody induction therapy, and subjects who had previously received or were receiving an organ transplant other than a kidney.
| Endpoints
| Pharmacokinetics
Primary pharmacokinetic variables, through Day 90, were AUC from 0 to infinity (AUC inf ), C max , and AUC from time 0 to the last quantifiable concentration (AUC last ). Secondary pharmacokinetic variables, through F I G U R E 1 Study design. *Day 0 Day 90, were time taken to reach the maximum concentration (t max ), half-life (t ½ ), volume of distribution (V z ), and total clearance (CL tot ).
Blood samples for pharmacokinetic analyses were obtained predose and 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48, 72, and 144 hours postinfusion, and on Days 15, 22, 29, 43, 60, 75, and 90 (or at the time of early discontinuation). All bleselumab concentration analyses were performed by a central laboratory (APGD Bioanalysis-US, Skokie, IL). 
| Pharmacodynamics
| Exploratory efficacy
| Safety and tolerability
Safety and tolerability variables, through Day 90, included adverse events (AEs) per National Cancer Institute Common Terminology Criteria for Adverse Events v4.02, antibleselumab antibodies, and new-onset diabetes mellitus (NODAT) in at-risk patients. Patients were considered at risk if they did not have diabetes (type I or II, or NODAT with prior transplant) present at skin closure, and did not have any pretransplant glucose value of >200 mg/dL or HbA1c value of ≥6.5%. Patients receiving antidiabetic treatment (eg, insulin or oral hypoglycemics) for ≥30 days pretransplant who did not discontinue antidiabetic treatment >7 days pretransplant were considered to have diabetes and thus were not included in the at-risk set.
| Statistical analyses
| Analysis sets
The full analysis set (FAS) and the safety analysis set (SAF) included all randomized patients who received study drug (bleselumab or placebo). The pharmacokinetic analysis set was composed of subjects from the SAF whom the pharmacokineticist considered to have adequate pharmacokinetic data for the calculation of the primary pharmacokinetic parameters. The pharmacodynamic analysis set included subjects from the SAF whom the pharmacokineticist considered to have adequate pharmacodynamic data for assessment of B cell CD40 receptor occupancy (the primary pharmacodynamic endpoint).
| Sample size
No statistical methods were used to determine the sample size. A planned sample size of 45 kidney transplant recipients (9 per treatment group) was consistent with other pharmacokinetic studies that were similar in design.
| Missing data
Patients lost to follow-up were included in the number of patients with graft loss and the number of deaths. No other imputation of missing data was done for this study. When deemed necessary, outliers for an individual's analyte concentration data were identified by pharmacokinetic plausibility and excluded from the primary analysis.
| Pharmacokinetics and pharmacodynamics
Individual patient serum bleselumab concentrations over time were used to derive pharmacokinetic parameters using a noncompartmental method with values below the lower limit of quantification set to 0. Dose proportionality was tested for primary pharmacokinetic outcomes. A 95% confidence interval (CI) for the true slope was constructed from the slope estimate (using linear regression on log e [pharmacokinetic parameter] against log e [dose]): if the 95% CI included the value of 1, dose proportionality was concluded. B cell CD40 receptor occupancy was summarized using descriptive statistics.
| RE SULTS
| Patient disposition and demographics
Overall, 50 patients were randomized to bleselumab or placebo ( Figure 2 ). Four randomized patients withdrew before receiving study drug and one patient was excluded owing to evidence of not taking the assigned study drug. Therefore, 45 patients were included in the SAF and FAS.
Overall, the majority of patients were male, white, and not Hispanic or Latino (Table 1 ). There were no females in the ble- The most frequently used concomitant immunosuppressant medications were tacrolimus, mycophenolate mofetil, and steroids.
Cyclosporine was used by only two patients (one each in the bleselumab 50 mg and 500 mg groups).
| Pharmacokinetics
Mean serum concentrations of bleselumab for the four active dose groups and placebo are shown in Figure 3 . C max was dose proportional (slope 1.03, 95% CI 0.92-1.13) but AUC showed a greater than proportional response: AUC inf (slope 1.74, 95% CI 1.60-1.88); AUC last (slope 1.77, 95% CI 1.63-1.92). As the dose increased, t ½ also increased, with a mean t ½ of approximately 25-169 hours over the bleselumab 50-500 mg dose range ( 
| Pharmacodynamics
Median B cell CD40 receptor occupancy was generally negligible in the placebo group but was demonstrated in the four active dose groups (Figure 4 ). In the bleselumab groups, median B cell receptor occupancy was at least 80% at 0.5 hours after dosing and remained at higher levels for longer periods of time with increasing doses. For the bleselumab F I G U R E 2 Patient disposition. *Four randomized patients withdrew before receiving study drug due to one AE during screening, one patient no longer fulfilled inclusion/exclusion criteria, two were never dispensed study drug. † one patient excluded from table summaries owing to evidence of not taking study drug. ‡ The one patient who received their treatment but did not complete the study in the bleselumab 50 mg group discontinued the study owing to not returning for their final visit. AE, adverse event; FAS, full analysis set; PDAS, pharmacodynamic analysis set; PKAS, pharmacokinetic analysis set; SAF, safety analysis set 50 mg group, median B cell CD40 receptor occupancy ranged from ~89% at 0.5 hours to ~76% at 144 hours, further decreased to ~5% 
| Exploratory efficacy
There were no deaths or graft losses. A total of six patients had BPAR, one of whom was in the placebo group (one patient in the bleselumab 500 mg group who experienced BPAR was excluded from table summaries owing to evidence of not taking study drug; Table S3 ). No patient had grade III T cell-mediated rejection or grade III antibody-mediated rejection. However, one patient in the bleselumab 500 mg group had grade IIA antibody-mediated rejection that started on Day 6 and ended on Day 13. No patient experienced multiple rejection episodes.
| Safety and tolerability outcomes
All patients in the study experienced ≥1 treatment-emergent AE (TEAE) during this study, most of which were grade I or II (Tables 3   and S3 ). Twelve patients (including three treated with placebo) experienced ≥1 serious TEAE, four of which were considered drug related (including one in the placebo group). The most commonly reported TEAEs in the active treatment groups were hypophosphatemia (54%), diarrhea (43%), hypomagnesemia (38%), tremor (30%), insomnia (30%), and edema peripheral (27%); in the placebo group, these were diarrhea (50%), vomiting (38%), tremor (38%), and headache (38%) ( Table S4) NODAT was detected in n = 2 of 7 at-risk placebo patients (29%) and 9 of 30 at-risk bleselumab patients (30%). NODAT was determined by identifying those who had oral hypoglycemic treatment for ≥30 consecutive days (4 bleselumab patients, 13.3%); those who reported insulin use for ≥30 consecutive days (3 of 30 bleselumab patients, 10%); those with a fasting glucose ≥126 mg/dL on two occasions at least 30 days apart (2 placebo patients, 29% and 4 active (Table S6) . No patient experienced a thromboembolic event during this study.
| D ISCUSS I ON
Treatment with various doses of bleselumab was not associated with significant immediate or long-term side effects, evidenced by a lack of cytokine release and an absence of thromboembolic complications. This is significant owing to the history of thromboembolic complications with CD154 antibodies 17 . This is similar data showed that C max increased dose proportionally but AUC increased more than dose proportionally, suggesting that bleselumab showed nonlinear pharmacokinetics. The mean t ½ of the two highest bleselumab doses, 200 mg and 500 mg, were 98 and 169 hours, respectively, suggesting that either dose could be given intermittently during long-term use to achieve prolonged drug exposure. As expected, pharmacodynamic analyses demonstrated that bleselumab was a nonagonistic blocking antibody. B cell depletion did not occur in patients treated with bleselumab, which is consistent with another study. 15 The current study also demonstrated no difference in total lymphocyte counts between the bleselumab-treated and con- The safety data derived from this phase 1b study are encouraging and a larger phase 2 study to assess both safety and efficacy is reported in this issue of American Journal of Transplantation (ClinicalTrials.gov NCT01780844). In nonhuman primate kidney transplant studies, bleselumab monotherapy prolonged graft survival but was more effective in combination with immunosuppressants as part of a CNI-free regimen. 18 Ultimately, a combination of agents, perhaps including a combination of costimulatory blockade with belatacept and an anti-CD40 monoclonal antibody, may be required to achieve efficacy and induce a tolerogenic immune environment. a One patient in the bleselumab 500 mg treatment group was excluded from table summaries owing to evidence of not taking study drug. b One patient in the bleselumab 50 mg group had a biopsy finding of minimal positive C4d staining and was counted as a biopsy-proven acute rejection in Table S3 . This was not reported as a treatment-emergent adverse event, so the count of kidney transplant rejection is one less in the bleselumab 50 mg group in Table 3 .
ACK N OWLED G M ENTS
